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Abstract 
Background: Sequential treatment of ankylosing spondylitis (AS) that includes tumour necrosis factor‑α antagonists 
(anti‑TNF agents) has been applied in most of the Western countries. Existing cost‑effectiveness (CE) models almost 
exclusively presented the incremental CE of anti‑TNF agents using a closed cohort while budget impact studies are 
mainly lacking. Notwithstanding, information on impact on total population health and societal budget as well as on 
actual incremental CE for a given decision time span are important for decision makers. This study aimed at quantify‑
ing, for different decision time spans starting from January 1, 2014 in the Dutch society, (1) impact of sequential drug 
treatment strategies without and with inclusion of anti‑TNF agents (Strategies 1 and 2, respectively) on total popula‑
tion health and societal cost, and (2) the actual incremental CE of Strategy 2 compared to Strategy 1.
Methods: Dynamic population modelling was used to capture total population health and cost, and the actual 
incremental CE. Distinguishing the prevalent AS population on January 1, 2014 and the incident AS cohorts in the 
subsequent 20 years, the model tracked individually an actual number of AS patients until death or end of the simula‑
tion time. During the simulation, data on patient characteristics, history of drug use, costs and health at discrete time 
points were generated. In Strategy 1, five nonsteroidal anti‑inflammatory drugs (NSAIDs) were available but anti‑TNF 
agents withdrawn. In Strategy 2, five NSAIDs and two anti‑TNF agents continued to be available.
Results: The predicted size of the prevalent AS population in the Dutch society varied within the range of 67,145–
69,957 with 44–46 % of the patients receiving anti‑TNF agents over the period 2014–2034. The use of anti‑TNF agents 
resulted in an increase in the annual drug costs (168.54–205.28 million Euros), but at the same time caused a decrease 
in the annual productivity costs (12.58–31.21 million Euros) and in annual costs of healthcare categories other than 
drugs (7.23–11.90 million Euros). Incremental cost (Euros) per QALY gained in Strategy 2 compared to Strategy 1 corre‑
sponding to decision time spans of 5, 10, 15 and 20 years improved slightly from 75,379 to 67,268, 63,938 and 61,129, 
respectively. At willingness‑to‑pay thresholds of 118,656, 112,067, 110,188 and 110,512 Euros, it was 99 % certain that 
Strategy 2 was cost‑effective for decision time spans of 5, 10, 15 and 20, respectively.
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Background
Ankylosing spondylitis (AS) is a chronic inflammatory 
rheumatic disease that imposes a considerable burden 
to the society [1, 2]. Main characteristics of AS include 
inflammation of the sacroiliac joints and the spine, which 
results in back pain and stiffness. The early onset of AS, 
mostly in the second and third decade of life, contrib-
utes to long-term functional impairments and a decrease 
in quality of life of the patients. Productivity loss due to 
sick leave and work disability in patients with AS has 
been found to be substantial [3]. Unfortunately, there 
is currently no cure for AS. Treatments of AS, conven-
tionally restricted to nonsteroidal anti-inflammatory 
drugs (NSAIDs) and physiotherapy, only relieve pain 
and stiffness without slowing down the disease progres-
sion [4]. Based on the evidence of large beneficial effects 
of tumour necrosis factor-α antagonists (anti-TNF 
agents) on symptoms of AS [5–8], these drugs have been 
approved for use in most of the Western countries from 
2002 onwards. In most guidelines for management of AS, 
treatment of AS is characterised by a sequence of drugs, 
in which the first anti-TNF agent is given to patients with 
persistently high disease activity despite adequate treat-
ments with two or more NSAIDs [9–12]. However, treat-
ment with anti-TNF agents is costly and places much 
pressure on the healthcare budget [13]. In societies that 
take into account economic consequences of new tech-
nologies, decisions on the coverage and reimbursement 
are based not only on the cost-effectiveness (CE) data, 
which represent the economic efficiency of the technolo-
gies, but also on the total cost of adopting the technolo-
gies and the national healthcare budgets, which are used 
to assess the technology affordability [14]. Thus, the over-
all health and budget impacts for a society are increas-
ingly receiving attention from the policy makers [15–18].
To capture the impact of inclusion of anti-TNF agents 
in the treatment strategy on total population health and 
cost over a specific period of time, the actual number of 
patients receiving anti-TNF agents during that period 
must be determined. This requires a dynamic popula-
tion approach, that is, new incident cases of AS as well as 
the AS patients leaving the population over time due to 
death should be taken into consideration. Also, changes 
over time in the number of AS patients who are eligible 
for anti-TNF agents need to be quantified. Using this 
approach, the actual incremental CE, i.e. incremental CE 
based on the total population cost and health over a real-
time period, can also be computed, which would be use-
ful to inform a decision that affects all actual patients in 
the healthcare system over a series of relevant time spans 
determined by a decision maker.
During the past decade, the incremental CE of thera-
pies with anti-TNF agents compared with the usual care 
has been investigated by several conventional model-
ling studies [13, 19, 20]. However, no published studies 
have attempted to predict the impact on total population 
health and societal cost as well as the actual incremen-
tal CE of the inclusion of anti-TNF agents in treatment of 
AS. One of the challenges in this prediction is to capture 
the dynamics of the AS population and the actual use of 
anti-TNF agents in the whole society. In a previous study 
[20], we developed a discrete event modelling framework 
to predict the incremental CE of a sequential treatment 
strategy including anti-TNF agents compared to usual 
care. Although this model took into consideration the eli-
gibility of a patient for an anti-TNF agent therapy, it did 
not account for new incident patients entering the sim-
ulation over time, and thus cannot be used to compute 
total population health and cost.
This study aimed at quantifying, for different time 
spans of decision within the period from January 1, 2014 
to January 1, 2034 in the Dutch society, (1) impact of 
sequential drug treatment strategies without and with 
inclusion of anti-TNF agents on total population health 
and societal cost, and (2) the actual incremental CE of 
inclusion of anti-TNF agents compared to usual care.
Methods
General modelling approach and treatment strategies
We developed a dynamic population model to simulate 
the impact of sequential treatment strategies without and 
with inclusion of anti-TNF agents on health and costs of 
all individual patients. The dynamics of the AS popula-
tion are characterised by real-life changes over time in 
its size (epidemiological aspect) and in the distributions 
of the characteristics of the patients (demographic and 
health aspects) and the distributions of the costs they 
incurred. These distributions are hereafter referred to 
Conclusions: Using the dynamic population approach, the present model can project real‑time data to inform a 
healthcare system decision that affects all actual number of AS patients eligible for anti‑TNF agents within different 
decision time spans. The predicted total population costs of different categories in the present study can help plan 
the organization of the healthcare resources based on the national budget for the disease.
Keywords: Budget impact, Health impact, Cost‑effectiveness, Cost‑utility, Discrete event simulation, Microsimulation, 
Modelling, Population dynamics, Tumor necrosis factor, Ankylosing spondylitis
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as AS population properties. Changes in the size of the 
AS population are determined by the size of the ini-
tial prevalent AS population, the incident cases joining 
the AS population over time, and the mortality of the 
patients. The incident cases represent newly diagnosed 
AS patients who come under care of the rheumatologists. 
The AS population properties can be captured by simu-
lating changes in characteristics and costs of individual 
patients. To track the patients individually, the patient-
level model (PLMod) developed by Tran-Duy et al. [20] 
was adapted and used in the present study. PLMod is a 
discrete event simulation model with three interrelated 
components, namely entity, states and events. An entity 
in PLMod is a patient characterized by age, gender, symp-
tom duration, diagnosis duration, work status (employed 
and work disabled), length of sick leave in one employed, 
disease activity (Bath AS Disease Activity Index, BASDAI 
[21]; scaled from 0 to 10 with higher values indicating 
worse disease activity), and functional status (Bath AS 
Functional Index, BASFI [22]; scaled from 0 to 10 with 
higher values indicating worse physical functioning). 
These characteristics were used to predict health utility, 
productivity costs and different categories of resource 
utilization. States in PLMod indicate whether a patient 
is receiving an NSAID, an anti-TNF agent or palliative 
care, or indicate whether BASDAI is decreasing, sta-
ble or increasing. These states were used to simulate the 
rheumatologist decision on the next treatment when the 
patient did not respond sufficiently to the current treat-
ment, or to determine possible events that may occur. 
Events in PLMod include BASDAI decrease or increase, 
loss of response to the current treatment, visit to a rheu-
matologist, occurrence of drug toxicity, selection and 
start of a new treatment, and death. During the simula-
tion, times to competing events were drawn from appro-
priate probability distributions and the patient “jumps” to 
the event with the shortest sampled time. Following the 
occurrence of an event, states and characteristics of the 
simulated patient were updated, based on which a next 
event was predicted. In brief, the simulation in PLMod 
starts with creation of a virtual patient with charac-
teristics sampled from appropriate distributions; then, 
PLMod simulates changes in BASDAI and BASFI of the 
patient under a specific treatment strategy and generates 
data on other characteristics, treatments, resource utili-
zation and quality adjusted life years (QALYs) at discrete 
time points until death or end of the simulation time. 
Extensive descriptions of the model structure, statisti-
cal models, mathematical relationships and the simula-
tion process can be found in the study by Tran-Duy et al. 
[20]  (main text and Web Only Data). As in PLMod, we 
used the same statistical models to link changes in BAS-
DAI to changes in BASFI, and to predict costs and QALYs 
using BASDAI, BASFI, age, gender, symptom duration 
and diagnosis duration as explanatory variables (for mod-
elling methods and parameter estimates, see Tran-Duy 
et al. [20], Web Only Data Appendix 3: Disease progres-
sion, resource utilization and health utility estimation). In 
the present model costs were aggregated into three main 
categories, which were drug cost, medical cost other than 
drug cost (including costs of hospitalisation and reha-
bilitation; visits to rheumatologists and other specialists, 
to general practitioners, and to nurse specialists, physi-
otherapists and psychotherapists; and formal and infor-
mal care), and productivity cost (including sick leave and 
work disability costs).
As in Tran-Duy et  al. [20], the recommendations for 
treatment of AS from the Assessment in SpondyloArthri-
tis International Society (ASAS) [9], which in many coun-
tries including The Netherlands have been adopted, were 
used to simulate the decision on starting and switching 
a drug based on BASDAI and the number of drugs that 
have been used. In the current prospective simulations, 
two treatment strategies were compared. In Strategy 1, 
anti-TNF agent would no longer be available from Janu-
ary 1, 2014 onwards; in Strategy 2, anti-TNF agents con-
tinued to be available. For the prevalent AS population on 
the starting date of the simulation, i.e. January 1, 2014, 
treatment history had to be simulated as there were no 
data available for the Dutch AS population on this date. 
Therefore, we performed two stages of simulation: (1) the 
burn-in stage in which a historical simulation was exe-
cuted, starting from January 1, 1996 where data on the 
prevalent Dutch AS population were available, to obtain 
characteristics and treatment history of the prevalent 
population on January 1, 2014, and (2) the main stage in 
which prospective simulations were executed to quan-
tify the AS population properties over time in different 
treatment strategies. For the incident cases, we assumed 
that no patients had received NSAIDs or anti-TNF agents 
before entering the simulation. Figure  1 conceptualises 
the main components and simulation process adapted 
from PLMod for use in the main stage of the current 
dynamic population model.
Opinion of rheumatologists were used to determine 
the maximal number of drugs in a sequential treatment 
strategy. In the historical simulation, a patient received 
a maximum of five NSAIDs during the life time, and a 
maximum of two anti-TNF agents from January 1, 2002, 
the date anti-TNF agents became reimbursed in The 
Netherlands, onwards. In the prospective simulations, a 
patient received a maximum of five NSAIDs in any strat-
egy taking into account the number of NSAIDs already 
received in the burn-in stage; and received no more anti-
TNF agent in Strategy 1, and a maximum of two anti-
TNF agents in Strategy 2, taking into account the number 
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of anti-TNF agents already received in the burn-in stage. 
In any simulation stage and treatment strategy, pallia-
tive care, i.e. the use of analgesics other than NSAIDs to 
alleviate symptoms, was given to the patient after failure 
of all the available drugs in the treatment. Algorithms 
for determining treatment failure and selecting a new 
treatment can be found in the study by Tran-Duy et  al. 
[20] (Web Only Data Appendix 1: Details on the simula-
tion process). Table  1 summarizes characteristics of the 
simulation stages and treatment strategies.
Dynamic population simulation
Given a decision time span of 20  years from January 1, 
2014 to January 1, 2034 in the prospective simulations, 
No 
No 
Death or end of the me horizon 
  BASDAI reaching 1 unit higher  
  End of BASDAI stability
  End of BASDAI decrease   
  BASDAI-related events 
Age, gender, BASDAI, BASFI, 
symptom duraon, work 
disable, having a paid job 
 Paent characteriscs 
Yes 
  On-BASDAI-decrease 
  On-BASDAI-stability 
  On-BASDAI-increase 
  BASDAI-related states 
Yes 
  NSAID-naive 
  On first NSAID 
  On second NSAID 
  On first an-TNF agent 
  On second an-TNF agent 
  On palliave care 
  Treatment-related states 
Number of NSAIDs and 
an-TNF agents the 
paent has received 
  Treatment history 
Sample mes to all 
possible events 
Determine the next event 
(Enext) 
Rheumatologist decision 
on a new treatment 
End simulaon  
Paent visit to a 
rheumatologist 
Designate paent states 
represenng the current 
treatment and trend of 
change in BASDAI 
Enext = Visit to a 
rheumatologist 
Enext = a BASDAI-
related event? 
Generate a 
new paent
Update paent 
characteriscs and 
compute costs and QALYs 
Absolute and relave 
changes in BASDAI 
Time on a treatment 
Number of drug failures 
 ASAS criteria 
Number of available 
NSAIDs and an-TNF 
agents in the treatment 
sequence 
 Treatment strategy 
In
te
rd
ep
en
de
nt
 
Fig. 1 Main components and simulation process of the patient‑level model used for tracking a patient with ankylosing spondylitis. For more infor‑
mation, see Tran‑Duy et al. [20]
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the model tracked individually all AS patients appear-
ing in The Netherlands during this period until death or 
end of the simulation time. The simulated patients com-
prised (1) the prevalent AS population (PP) on January 1, 
2014, and (2) the yearly incident AS cohorts (ICs) in the 
subsequent years. The size of the PP was obtained from 
the historical simulation. The size of IC in each year was 
computed as the product of the size of mid general Dutch 
population in that year and the incidence rate of AS per 
year, which was assumed to be constant. To track the 
patients in each IC, a number of patients equalling the 
calculated size of the IC were created; for each patient, 
a set of characteristics were sampled based on appropri-
ate probability distributions, which were assumed to be 
time-independent. For all the incident patients within a 
year, diagnosis duration was set at 0 when the patients 
enter the simulation assuming that a possible delay in 
diagnosis has no influence on the treatment selection or 
course of the disease. Figure 2 illustrates the concepts of 
the dynamic population simulation in the main stage. The 
same concepts were applied in the burn-in stage except 
for the start and end dates being January 1, 1996 and 
January 1, 2014, respectively, and the size of the PP being 
calculated as the product of the size of the general popu-
lation on January 1, 1996 and the prevalence of AS, which 
was assumed to be constant.
Model parameterization
We estimated probability distributions of the patient 
characteristics in the PP on January 1, 1996 and in the 
ICs using the data sources from the Outcomes Assess-
ment in AS International Study (OASIS) [23] and expert 
opinion. Types and parameter estimates of the distribu-
tions of the characteristics are provided in Table 2. Since 
no recent data on incidence or prevalence of AS were 
available for The Netherlands, we set the AS prevalence 
at 0.4 %, as reported for Western countries in studies on 
the epidemiology of AS [24–26]. Studies in Spain, Fin-
land and Northern Norway showed incident rates around 
7 cases per 100,000 person-year [26–28]. We used this 
value as an initial point and calibrated it to obtain a mean 
prevalence of 0.4 % and a smallest variance of the simu-
lated prevalence proportions at yearly time points. We 
derived the size of the general population on January 1 of 
each year and estimated mortality rate based on Statistics 
Netherlands [29]. We estimated drug efficacies based on 
literature, and costs and health utility (EQ-5D) using data 
from the OASIS [23]. A list of parameter estimates and 
detailed methods for parameter estimation are provided 
extensively in Tran-Duy et al. [20]. We assumed that the 
discontinuation of anti-TNF agents on Jan 1, 2014 in 
Strategy 1 caused a rebound of disease activity (BASDAI) 
to the baseline within 12 weeks based on expert opinion 
and observations in patients withdrawing from clinical 
trials [30].
Budget and health impact analyses
Costs incurred by and QALYs of each patient were com-
puted for the period from the time point that the patient 
entered the simulation to death or January 1, 2034, 
whichever came first. Productivity costs were computed 
using the human capital approach [31]. Total population 
cost on January 1 of a specific year after 2014 was calcu-
lated as the sum of all costs due to AS in the period from 
January 1, 2014 to the respected year. Similarly, total 
population QALYs on January 1 of a specific year for the 
whole society were calculated as the sum of QALYs of all 
subjects having been diagnosed with AS by a rheuma-
tologist between January 1, 2014 and the respected year. 
For probabilistic sensitivity analysis (PSA), values of the 
Table 1 Characteristics of the simulation stages and treatment strategies
NSAIDs non‑steroidal anti‑inflammatory drugs, anti-TNF agent tumour necrosis factor‑α antagonist
Burn-in stage (historical simulation) Main stage (prospective simulation)
One treatment strategy Treatment strategy 1 Treatment strategy 2
Time horizon 1 Jan 1996–1 Jan 2014 1 Jan 2014–1 Jan 2034 Same as treatment 
Strategy 1
Maximal number of drugs a patient can receive
 NSAIDs Five, randomly selected from ten possible drugs
After failure of two NSDAIs, the next two anti‑TNF  
agents are considered; the remaining NSAIDs are 
reserved for those failing both anti‑TNF agents
Five in an uninterrupted sequence, randomly 
selected from ten possible drugs
Same as in the burn‑in 
stage
 Anti‑TNF  
agents
Two, one subcutaneous and another intravenous,  
available from 1 Jan 2002 onwards
After failure of two anti‑TNF agents, the remaining 
NSAIDs are considered
No longer available Same as in the burn‑in 
stage
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model parameters were sampled 10,000 times from the 
appropriate distributions; for each set of parameter val-
ues the simulation was run over the periods of 5, 10, 15 
and 20  years starting from January 1, 2014. Net-benefit 
framework was used to construct the cost-effectiveness 
acceptability curves from the Monte Carlo simulation 
results [32].
Modelling tools and model validation
We used the Delphi language (Embarcadero Delphi XE 
2010, Embarcadero Technologies Inc, San Francisco, 
US) to program the dynamic population model, in which 
PLMod was integrated as an encapsulated module to 
generate outcomes of each patient from the model inputs. 
We used R [33] to analyse the simulated longitudinal 
outcomes of all individual patients. The model was rig-
orously checked for syntactical and logical errors. Simu-
lated results were face-to-face validated by experts in AS 
and health economists.
Results
Predicted prevalent population on January 1, 2014
On January 1, 2014, the predicted numbers of male and 
female AS patients were 46,528 and 20,617, respectively; 
the simulated proportion of patients with paid jobs was 
0.76, and proportion of patients with (partial) work dis-
ability was 0.19; the predicted numbers of patients 
receiving <2, 2 and >2 NSAIDs were 29,116, 7936 and 
30,093; the predicted numbers of patients receiving 0, 1, 
and 2 anti-TNF agents were 37,467, 16,290 and 13,388. 
Fig. 2 Conceptual model of the dynamic population simulation. Each solid circular dot on the left margin represents an AS patient at the time point 
when he or she enters the simulation. The patients are differentiated into groups, including the prevalent population on 1 January 2014 and inci‑
dent cohorts in years 2014–2034, whose sizes are calculated based on the sizes of the general population and prevalence and incident rate. Each 
solid horizontal line represents the temporal movement of each patient, which ends when the patient dies (marked with a solid diamond) or reaches 
January 1, 2034 (marked with an open circle on the vertical bar on the right margin). The open circles represent the patients in the prevalent popula‑
tion at a time point of interest who are included in the summary statistics of disease measures, costs and health utilities
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Summary statistics of the numeric characteristics of 
these patients are given in Table 3.
AS population properties between January 1, 2014 
and January 1, 2034
The predicted size of the prevalent AS populations at 
yearly time points between January 1, 2014 and Janu-
ary 1, 2034 varied within the range of 67,145–69,957, 
corresponding to a prevalence of approximately 0.4  %. 
Forty-four to 46 percent of the patients received anti-
TNF agents over the period from 2014 to 2034. The num-
bers of AS patients with low BASDAI in the intervals [0, 
2) and [2, 4) were higher in Strategy 2 than in Strategy 
1, while those with moderate to high BASDAI in the 
intervals [4, 6) and [6, 8) were higher in Strategy 1 than 
in Strategy 2 over time (Fig. 3; the square bracket or the 
parenthesis at one end of an interval indicates that its 
adjacent endpoint is included or excluded, respectively). 
Differences in the number of AS patients with very high 
BASDAI in the interval [8, 10] were negligible  between 
the two strategies. Inclusion of two anti-TNF agents in 
the AS treatment (Strategy 2) affects the numbers of AS 
patients with BASDAI in the intervals [4, 6) and [0, 2] 
more pronouncedly in the other intervals.
Changes over time in mean BASDAI and BASFI of 
the AS population in both strategies followed the same 
trends. When only NSAIDs but no anti-TNF agent were 
available after January 1, 2014 (Strategy 1), mean BAS-
DAI and BASFI over 12  weeks increased from 2.97 to 
3.55, and from 3.93 to 4.45, respectively. After March 
2014, mean BASDAI and BASFI slightly increased dur-
ing the next 10 years and then remained almost constant 
during the period from 2024 to 2034 at 3.87 and 4.91, 
respectively. Ranges of means (SDs) of BASDAI and 
BASFI at yearly time points over 20 years were 2.97–3.89 
(1.51–1.59), and 3.93–4.94 (1.86–1.95), respectively.
When two anti-TNF agents remained available after 
January 1, 2014 (Strategy 2), there was almost no change 
in mean BASDAI and BASFI over time; means (SDs) 
of BASDAI and BASFI at yearly time points between 
January 1, 2014 and January 1, 2034 ranged from 2.97 
Table 2 Types and  parameter estimates of  the distributions of  the patient characteristics in  the prevalent population 
on January 1, 1996 and in each yearly incident cohort
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index
a N (m, s): Normal distribution with mean m and standard deviation s; Bern (p): Bernoulli distribution with probability of true value being p
b Distribution conditional on age; parameters estimated by fitting a linear model using generalized least squares with fixed variance weights
c Distribution of square root of the respective characteristics
d Distribution conditional on BASDAI
Characteristics Distributiona
Prevalent population (PP)
Estimated size: 62,000 patients
Yearly incident cohort
Estimated size: 1000–1200 patients
Age of male N (42.5, 12.6) N (33.7, 8.14)
Age of female N (46.3, 12.7) N (33.7, 8.14)
Gender (male) Bern (0.69) Same as PP
Symptom duration N (0.64 × Age − 7.76, 1.20 × √Age)b Same as PP
Diagnosis duration N (3.1, 1.3)c 0
Proportion of patients with paid jobs Bern (0.75) Same as PP
Proportion of paid‑job patients being work disabled Bern (0.20) Same as PP
Contraindication to anti‑TNF agents Bern (0.20) Same as PP
BASDAI N (1.72, 0.63)c N (1.91, 0.52)c
BASFI of male patient N (0.69 × BASDAI + 1.89, 1.69)d N (0.60 × BASDAI + 2.62, 1.42)d
BASFI of female patient N (0.92 × BASDAI + 0.19, 1.00)d N (0.91 × BASDAI + 0.27, 0.81)d
Table 3 Characteristics and treatment history of the simu-
lated population  of patients with  ankylosing spondylitis 
on January 1, 2014
BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath 
Ankylosing Spondylitis Functional Index
Attribute Summary statistics of the 67,145 
patients in the Dutch society based 
on the simulated data
Min Median Mean (SD) Max
Age of male 15.6 43.2 43.8 (12.2) 80.5
Age of female 15.7 43.5 44.2 (12.3) 80.4
Symptom duration (year) 0 25.2 25.1 (10.8) 78.5
Diagnosis duration (year) 0 14.3 15.9 (10.7) 54.8
BASDAI (on 1–10 scale) 0 2.66 2.97 (1.57) 8.96
BASDFI (on 1–10 scale) 0 3.86 3.93 (1.92) 9.81
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to 3.13 (1.53–1.61), and from 3.93 to 4.12 (1.85–1.93), 
respectively.
In line with changes in mean BASDAI and BASFI, 
mean health utility quickly decreased in Strategy 
1 from 0.59 to 0.52 within 3  months, after which it 
slightly decreased during the next 10  years and then 
remained almost constant at 0.48 until 2034. In Strat-
egy 2 mean health utility remained almost constant at 
0.59 over the period from January 1, 2014 to January 1, 
2034.
Budget and health impacts, and incremental 
cost-effectiveness
Cumulative societal total population costs (in million 
Euros) incurred by all actual AS patients in the Dutch 
Society from January 1, 2014 onwards, based on the cur-
rent prices assuming no inflation or major change in 
treatment options, on January 1 of 2019, 2024, 2029 and 
2034 would be 3412.03, 6786.76, 10,139.94 and 13,481.54 
in Strategy 1, respectively, and 4113.66, 8126.46, 
12,089.74 and 16,022.27 in Strategy 2, respectively. Total 
annual direct and productivity costs (in million Euros) in 
Strategy 1 ranged from 290.58 to 326.02, and from 344.86 
to 381.05, respectively. In Strategy 2, total annual direct 
and productivity costs (in million Euros) ranged from 
470.61 to 496.88, and from 323.05 to 354.95, respectively. 
The use of anti-TNF agents resulted in an increase in the 
annual drug costs (€168.54–205.28 million Euros), but at 
the same time caused a decrease in the annual produc-
tivity costs (€12.58–31.21  million Euros) and in annual 
costs of healthcare categories other than drugs (€7.23–
11.90 million Euros).
Cumulative QALYs of all actual AS patients in the 
Dutch society since January 1, 2014 on January 1 of 
2019, 2024, 2029 and 2034 would be 239,174, 462,920, 
687,465 and 903,983, respectively, in Strategy 1, and 
would be 248,482, 482,831, 717,960 and 94,5546, 
respectively, in Strategy 2. The use of anti-TNF agents 
resulted in an increase in the annual total QALYs of 
1628–2206.
Incremental cost (€) per QALY gained (iCER) in Strat-
egy 2 compared with Strategy 1 on January 1 of 2019, 
2024, 2029 and 2034 improved slightly from 75,379 to 
67,268, 63,938 and 61,129, respectively.
Probabilistic sensitivity analysis
The scatterplot of the joint uncertainty in the incremental 
total population costs against incremental total popula-
tion QALYs on January 1 of 2019, 2024, 2029 and 2034 
in Strategy 2 compared with Strategy 1 showed all data 
points lying within the north-east quadrant of the cost-
effectiveness plane (Fig. 4). The boundaries of incremen-
tal cost and QALY and the ranges of incremental cost 
and QALY increased with increasing time horizons. At 
willingness-to-pay amounts for one QALY gain (WTPs) 
of €75,870, €67,885, €64,663 and €61,783, the probabili-
ties that Strategy 1 and Strategy 2 are cost-effective were 
equal (0.5) on January 1 of 2019, 2024, 2029 and 2034, 
respectively. At WTPs of €118,656, €112,067, €110,188 
and €110,512, it was 99  % certain that Strategy 2 was 
Fig. 3 Changes over time in the number of patients with BASDAI within a specific interval in two treatment strategies. Strategy 1 consists of five 
available non‑steroidal anti‑inflammatory drugs (NSAIDs) and Strategy 2 consists of the same available NSAIDs as in Strategy 1 and two tumour 
necrosis factor‑α antagonists
Page 9 of 12Tran‑Duy et al. Cost Eff Resour Alloc  (2015) 13:18 
cost-effective on January 1 of 2019, 2024, 2029 and 2034, 
respectively (Fig. 5).
Discussion
Budget impact analysis (BIA) is increasingly becoming 
a required part of economic evaluation of a new health 
intervention [34]. In the Netherlands and many other 
countries like England, USA and Australia, reimburse-
ment of a new drug is based not only on CE information 
but also on an additional appraisal that includes societal 
cost impact of the drug treatment on the national health 
and healthcare budget [14, 35]. However, in most stud-
ies the BIA has been carried out independently of health 
impact analysis and analysis of the actual incremental 
CE. As a consequence, the information provided has 
usually been incomplete for a healthcare system deci-
sion that takes the outcomes of any patients receiving 
the intervention into consideration. In the present study 
we used a state-of-the art approach to quantify the total 
population health and societal cost associated different 
treatment strategies for AS, and derived the actual iCER 
of the treatment including anti-TNF agents compared 
with usual care for different time spans of decision. In 
AS, so far the CE of anti-TNF agents reported in the liter-
ature has been analysed using a closed cohort of patient 
with arbitrary initial sizes. Except for the study by Tran-
Duy et al. [20], all the studies compared a single anti-TNF 
agent with usual care and reported iCERs for inflixi-
mab, etanercept and adalimumab being in the ranges of 
€5307–€237,010, €29,815–€123,761 and €7344–€33,303, 
respectively [19]. In the study by Tran-Duy et  al. [20], 
CE of sequential treatment strategies rather than sin-
gle drugs were modelled and the computed iCER of the 
treatment strategy that included both NSAIDs and anti-
TNF agents compared to the treatment strategy that 
included only NSAIDs was €35,186. Although the pre-
sent model adopted the same setting for comparators and 
the same equations for computing costs and QALYs, its 
predicted iCERs were higher than the iCER in Tran-Duy 
et al. [20]. This difference in iCERs was due to the differ-
ence in the patient populations considered in the models. 
In Tran-Duy et al. [20], a closed cohort of 13,000 newly 
diagnosed cases, determined based exclusively on tech-
nical aspects, was used for the simulation, and the size 
of this cohort decreased over time. In contrast, the pre-
sent model started with a realistic prevalent population 
of 67,145 patients, and the size of the prevalent popula-
tion slightly increased over time as a result of increased 
sizes of the incident cohorts who entered the simulation 
over time. The effect of incorporating population dynam-
ics on the model outcomes can easily be seen via changes 
in disease measures. After 6 months since the start of the 
simulation, the simulated mean BASDAI and BASFI in 
Tran-Duy et al. [20] increased over time, but those in the 
current study were quite stable. This implies that incor-
porating the population dynamics in the model affects 
both the incremental cost and incremental QALYs of the 
treatment strategy with anti-TNF agents, and therefore 
iCERs, because BASDAI and BASFI influence resource 
utilisation and health utility.
The difference in the predicted iCER between the 
closed cohort model in Tran-Duy et  al. [20] and the 
dynamic population model in the present study is in line 
with the findings of Hoyle and Anderson [36]. Using alge-
braic expressions, the authors of that study [36] showed 
that the iCER computed by a conventional CE analy-
sis may substantially differ from that by the model that 
includes both prevalent and incident cohorts, especially 
when the discount rates for costs and QALYs are une-
qual. In The Netherlands, the annual discount rates for 
costs of 4.0 % and for QALY of 1.5 % are recommended 
[35], which were used in both our previous [20] and 
present models. The findings from our studies argue 
Fig. 4 Scatter plot of incremental total population costs against 
incremental total population quality‑adjusted life year (QALYs) in 
Strategy 2 (alternative) compared to Strategy 1 (reference). Strategy 
1 consists of five available non‑steroidal anti‑inflammatory drugs 
(NSAIDs) and Strategy 2 consists of the same available NSAIDs as in 
Strategy1 and two tumour necrosis factor‑α antagonists. The clouds 
corresponding to January 1 of 2019, 2024, 2029 and 2034 were 
obtained from simulations with four different time spans of decision, 
5, 10, 15 and 20 years, respectively. In each cloud, each data point was 
obtained from one run of simulation for all the AS patients appearing 
in the period from January 1, 2014 to the end of the corresponding 
time span with a set of model parameter values sampled from appro‑
priate probability distributions; 10,000 runs were executed which 
resulted in 10,000 data points. All the data points in the four clouds lie 
in the north‑east quadrant of the plane
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in favour of the suggestion of Hoyle and Anderson [36] 
that, to inform a decision that affects costs and benefits 
of all patients in the healthcare system, a CE analysis 
should include both prevalent and future incident patient 
cohorts.
Despite the difference in the modelling approach, 
both study by Tran-Duy et  al. [20] and the current 
study showed that inclusion of anti-TNF agents in the 
sequential treatment of AS would be cost-effective in 
The Netherlands, where the maximal acceptable willing-
ness-to-pay (WTP) threshold is suggested to be around 
€80,000 per QALY [37]. The findings from the present 
study also indicate that given a WTP threshold, the cer-
tainty in decision on the CE of using anti-TNF agents in 
the treatment of AS is influenced by the time frame of 
the assessment. For example, while it was 50  % certain 
that the use of anti-TNF agents over 20 years was cost-
effective, it was only 10  % certain that the use of anti-
TNF agents over 5 years was cost-effective, given a WTP 
threshold of €61,783 per QALY.
We showed that retaining anti-TNF agents in manage-
ment of AS would result in substantial gain in health for 
the population compared with the treatment strategy 
that withdraws anti-TNF agents. In addition, 10 % of the 
increase in the annual medication expenditures due to 
the use of anti-TNF agents would be compensated by the 
financial return from increased productivity and reduced 
need for hospitalisations. By partitioning the costs into 
different categories and computing them at different time 
points after the introduction of the new treatment option 
in real life, the model results can be used to better inform 
decisions on organisation of healthcare resources at the 
regional and/or national level.
In a dynamic population model, changes in the patient 
population properties over time are influenced by the 
incidence and mortality rates, and the distributions of 
patient characteristics of the initial prevalent popula-
tion and of the subsequent incident cohorts. A literature 
review showed that these data in AS are still scarce [38], 
which suggests that a thorough study on demography 
and epidemiology of the AS population in the modelled 
society should be conducted. We assumed that preva-
lence and incidence rate were constant but in reality they 
may decrease over time with better prevention and treat-
ments. Predicting the trend of changes in these quantities 
is challenging; therefore, it is worthwhile to analyse sce-
narios with different trends of change in prevalence and 
incident rate in a dynamic population model.
Conclusions
Using the dynamic population approach, our model can 
project real-time data to inform a healthcare system 
decision that affects all actual number of AS patients 
eligible for anti-TNF agents within different time spans 
of decision. The predicted total population costs of dif-
ferent categories in the present study can help plan the 
organization of the healthcare resources based on the 
national budget for the disease. The use of anti-TNF 
agents in a dynamic population would be marginally 
acceptable in The Netherlands. Our study showed the 
Fig. 5 Cost‑effectiveness acceptability curves for two treatment strategies based on the uncertainty in cost and quality‑adjusted life year (QALY) on 
January 1 of 2019, 2024, 2029 and 2034. Strategy 1 consists of five available non‑steroidal anti‑inflammatory drugs (NSAIDs) and Strategy 2 consists 
of the same available NSAIDs as in Strategy 1 and two tumour necrosis factor‑α antagonists (anti‑TNF agents). The four curves were obtained from 
simulations with four different time spans of decision, 5, 10, 15 and 20 years
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knowledge gaps with regards to the prevalence and inci-
dent rate and the distributions of the patient character-
istics in the prevalent population and incident cases, 
suggesting a need for conducting relevant studies to fill 
these gaps.
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